Sanofi SNY , Eli Lilly & Company’nin LLYbülten hızlı etkili insülin, Humalog (insülin lispro) ‘ un biyo- benzeri versiyonu olan Admelog için FDA onayı aldı . Admelog teknik olarak şu ana kadar 2017 yılında 2,08 milyar dolarlık satış kaydedilen Humalog’un biyolojik sürümüdür.
Sanofi SNY received FDA approval for Admelog, its biosimilar version of Eli Lilly & Company’s LLY blockbuster rapid-acting insulin, Humalog (insulin lispro). Admelog is technically a follow-on biologic version of Humalog, which recorded sales of $2.08 billion in 2017 so far.
Admelog is the first follow-on Humalog product to be approved by the FDA to help adult patients with type II diabetes and children (3 years and older) with type I diabetes manage their blood sugar levels at mealtime.
Admelog (100 Units/mL) will be available in the United States in vial and SoloStar pen. Please note that Admelog received marketing approval in the EU in July this year.
Sanofi’s shares have risen 8% so far this year, comparing unfavorably with a gain of 15.6% recorded by the industry .
Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus, facing increasing competitive pressure at the payor level and biosimilar competition in several European markets and Japan. Moreover, a follow-on product to Lantus hit the market in the form of Lilly and Boehringer Ingelheim’s, Basaglar in mid-December 2016.
In 2017 so far, Lantus sales have declined 24.9% in the United States due to lower average net price and exclusion from the CVS Health Corporation CVS and United Health formulary plans. U.S. diabetes sales have declined 20.2% so far in 2017.
In fact, U.S. diabetes franchise sales are expected to decline at an accelerated rate in the fourth quarter due to CVS/United Health formulary exclusion plans, continued lower average pricing and difficult comparisons with the last year.
Sanofi carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
A better-ranked large-cap pharma stock is H. Lundbeck A/S HLUYY carrying a Zacks Rank #2 (Buy).
Shares of Lundbeck have risen 19.4% so far this year while 2018 earnings estimates have gone up 3.2% in the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don’t buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
H Lundbeck A/S (HLUYY): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
